Received FDA orphan drug designation for the treatment of dermatomyositis in April 2017. Received FDA approval for the treatment of dermatomyositis in adults in July 2021. In ITP, Octagam 10% ...

These results highlight Ruxoprubart’s potential as a safe and effective treatment for DM and other complement-mediated diseases. Dermatomyositis (DM) is a rare idiopathic inflammatory condition ...

Myositis-specific autoantibodies (MSAs ... She is recognized for her contributions to advancing treatment options and understanding of these challenging conditions. Financial Disclosures: Dr ...

Lundberg agrees: “It would be very interesting to test treatment with IL-6 antibodies in patients with polymyositis, and probably also dermatomyositis.” ...

1 Centro Hospitalar de Entre o Douro e Vouga – Physical and Rehabilitation Medicine Department – Santa Maria da Feira, Portugal 2 Physical and Rehabilitation Medicine – Portugal Myositis ossificans ..